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Summary
Breast cancer is the most common cancer in females and it is primarily disease of ageing with highest incidence in 
women older than 65 years. There are statistically signifi cant diff erences in breast cancer histology considering patients age 
and older patients are usually diagnosed with larger, hormone sensitive tumors. Approximately 15-25% of all women diag-
nosed with early breast cancer have tumor overexpressing HER2/neu receptor. A golden standard for early and metastatic 
HER2 positive breast cancer treatment is trastuzumab. Studies in adjuvant sett ing showed that one year of trastuzumab 
therapy reduces the risk of death by one-third. Important side eff ect of trastuzumab treatment is cardiotoxicity, whose pre-
cise mechasnisms are not clear yet. The aim of our study was to determine diff erences in biological characteristics of tumor, 
treatment options and cardiac side eff ects in elderly patients with HER2 positive early breast cancer. Research included 
patients with early, histologically confi rmed, HER2 positive breast cancer who underwent prior breast surgery and axillary 
node dissection. Patients were divided into two groups considering age: group I ≤ 65 years of age and group II > 65 years of 
age. Patients received adjuvant anthracycline or non-antracycline based chemotherapy followed by one year of trastuzumab 
monotherapy. Cardiac function was monitored with echocardiography by measuring left ventricle ejection fraction (LVEF) 
in patients before starting trastuzumab, 3 months and 8 months after trastuzumab was introduced. Incidence of trastu-
zumab induced cardiac dysfunction showed no signifi cant diff erence between younger and older patients except in group 
of older patients with cardiovascular risk who had signifi cantly higher incidence of cardiac dysfunction.
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HER2 POZITIVNI KARCINOM DOJKE U STARIJIH BOLESNICA: 
BIOLOGIJA TUMORA I SPECIFIČNOSTI SISTEMSKOG LIJEČENJA
Sažetak
Karcinom dojke je najčešći karcinom u žena i primarno je bolest starenja s najvećom incidencijom u žena dobi iznad 65 
godina. Postoje statistički značajne razlike u histologiji karcinoma dojke obzirom na dob bolesnice i starije bolesnice obično 
imaju veći, hormonski ovisan tumor. 15-25% svih žena kojima se dijagnosticira rani karcinom dojke imaju tumor koji pretje-
rano eksprimira HER2/neu receptor. Zlatni standard za liječenje ranog i uznapredovalog HER2 pozitivnog karcinoma dojke 
je trastuzumab. Studije u adjuvantnom liječenju su pokazale da jednogodišnje terapija trastuzumabom smanjuje rizik od 
smrti za jednu trećinu. Važna nuspojava liječenja trastuzumabom je kardiotoksičnost, čiji mehanizmi nastanka još nisu 
potpuno razjašnjeni.
Cilj našeg istraživanja je bio utvrditi razlike u biološkim karakteristikama tumora, terapijskim opcijama i kardijalnim 
nuspojavama u starijih bolesnica s ranim HER2 pozitivnim tumorom dojke.
U istraživanje smo uključili bolesnice s ranim, histološki potvrđenim, HER2 pozitivnim karcinomom dojke koje su 
ranije liječene kiruški, operacijom dojke i odstranjenjem aksilarnih limfnih čvorova. Bolesnice su podijeljene u dvije skupine 
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obzirom na dob: grupa I – mlađe od 65 godina i grupa II – starije od 65 godina. Bolesnice su primile adjuvantnu kemotera-
piju na bazi antraciklina ili protokolom bez antraciklinskog preparata nakon čega je slijedilo liječenje trastuzumabom u 
monoterapiji kroz godinu dana. Srčana funkcija je praćena uz pomoć ehokardiografi je, mjerenjem ejekcijske frakcije lijevog 
ventrikla prije početka terapije trastuzumabom te 3 i 8 mjeseci nakon početka terapije trastuzumabom.
Incidencija trastuzumabom inducirane kardiotoksičnosti nije pokazala statistički značajnu razliku između mlađih i 
starijih bolesnica, osim u grupi starijih bolesnica sa kardiovaskularnim rizikom, koje su imale značajno veću incidenciju 
srčanog popuštanja.
KLJUČNE RIJEČI: karcinom dojke, HER2 pozitivan, trastuzumab, srčano popuštanje
INTRODUCTION
Breast cancer is the most common cancer in 
females and it alone contributes 25% of new can-
cer cases in the world. Breast cancer is primarily 
disease of ageingwith an incidence rate (USA) of 
82,2 per 100000 in women younger than age 65 
years versus 403,8 per 100000 for those age 65 
years and older. The average age at diagnosis is 61 
years and the average age at death is 68 years (1).
In the UK the majority of breast cancers are diag-
nosed in women over 50 years of age, of which 
31% are in patients aged 70 and over (2). In most 
countries about 40% of breast cancer cases occur 
in women aged 65 years and older, and the inci-
dence of breast cancer among older women is ex-
pected to increase in the future (3). Ageing and 
severe comorbidities reduce tolerance to treat-
ments which should be considered when choos-
ing the appropriate therapy for elderly patients 
(3,4).Elderly women are often diagnosed at the 
late stage due to delayed physician visit. 3% of 
women in the 50-69 age group are diagnosed at 
the late stage, 8% of women aged over 70 years 
have a late stage at diagnosis which diminishes 
survival rate (5).Croatian demographic statistics 
show trend of ageing population and the country 
has one of the highest percentages of population 
over 65 years. According to Croatian National 
Cancer Register data there were 2500new cases of 
breast cancer registered in 2010 and 1100 regis-
tered deaths from breast cancer (6).Incidence and 
mortality grow continuously. Since October 2006 
Croatian government started National program 
for early breast cancer detection Mamma which 
consists of mamography examination every two 
years for all females aged 50 to 69 years (7).
There are statistically signifi cant diff erences 
in breast cancer histology considering patients age 
and older patients usually have larger hormone 
sensitive tumor(8).Approximately 15-25% of all 
women diagnosed with early breast cancer have 
tumor that overexpresses HER2/neureceptor which 
is result of exessive amplifi cation of erbB2 gene 
(9,10). Patients with breast cancer in which HER2 
is overexpressed are likely to have poorly diff er-
entiated tumors with a high proliferative rate, 
positive axillary lymph nodes, and decreased ex-
pression of estrogen and progesterone receptors. 
These characteristics are associated with an in-
creased risk of disease recurrence and death 
(11,12). A golden standard for early and metastatic 
HER2 positive breast cancer treatment is trastu-
zumab, recombined humanizedmonoclonal anti-
body (IgG) with high affi  nity for the extracellular 
domain of erbB2 (HER2) transmembrane receptor 
(11–13). The combination of trastuzumab and a 
chemotherapeutic agent improves 1-year survival 
in women with metastatic breast cancer by 16% 
(14–18). Phase three studies in adjuvant treatment 
NSABP-B31 (National Surgical Adjuvant Breast 
end Bowel Project),NCCTG N 9831 (North Central 
Cancer Treatment Group), HERA (Herceptin Ad-
juvant trial)and BCIRG 006 (Breast Cancer Inter-
national Research Group) showed clinical benefi t: 
one year of trastuzumab therapy reduces the risk 
of death by one-third (10,19–23). Clear clinical 
benefi t of trastuzumab therapy is shown after few 
years: in the 4-year follow-up of the joint effi  cacy 
analysis from NSABP B-31 and NCCTG N 9831, 
the addition of trastuzumab to chemotherapy re-
sulted in a 48% reduction in DFS events, and 93% 
of patients who recived trastuzumab were alive 4 
years after diagnosis (24). Important side eff ect of 
trastuzumab treatment is cardiotoxicity, whose 
precise mechasnisms are not clear yet(11). HER2 
in myocytes plays important role in embryogene-
sis, contractility and cell death (11,25–28). Binding 
to HER2 receptor, trastuzumab blocks activity of 
neuregulin 1β, paracrine mediator that aff ects 
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contractility and cell proliferation, which leads 
to cardiac dysfunction (29–31). Clinical studies 
showed 6.2% (HERA) to 19% (NSABP-B32) sus-
pension of trastuzumab therapy due to decrease 
in LVEF (25).
Adjuvant chemotherapy improves survival 
in women with early breast cancer. Age, comor-
bidity and life expectancy should be considered 
when choosing the appropriate adjuvant treat-
ment. Women aged 50–69 years with breast cancer 
achieve a 20% proportional reduction in the risk 
for recurrence and an 11% proportional reduction 
in the risk for death with adjuvant chemotherapy 
(3). There are limited data on chemotherapy ben-
efi t in patients over 70 years of age due to lower 
percentage of elderly patients included in fewer 
clinical trials.
The Early Breast Cancer Trialists Collabora-
tive Group (EBCTCG) meta-analysis, which in-
cluded as few as 1,529 patients aged >70 years in 
comparison with more than 31,000 patients <70 
years, found a nonstatistically signifi cant 13% re-
duction in all-cause mortality among women aged 
70 years and older who received adjuvant chemo-
therapy. Life expectancy represents a central con-
cept in decision making in the elderly patient with 
breast cancer, because treatment options now 
available often carry risks and toxicities in older 
women. Nonlinear relationship between age and 
life expectancy is crucial in clinical decision mak-
ing: women aged 65, 75, and 85 years in good 
health can expect to live, on average, an additional 
20, 12, and 6 years, respectively. The choice of ad-
juvant treatment for elderly patients should be 
based on the same criteria that are currently used 
for other age groups (3).
AIM
To determine diff erences in biological char-
acteristics of tumor, treatment options and cardiac 
side eff ects in elderly patients with HER2 positive 
early breast cancer.
MATERIALS AND METHODS
Research included patients with early, histo-
logically confi rmed, HER2 positive breast cancer 
who underwent prior breast surgery and axillary 
node dissection. Patients were divided into two 
groups considering their age: group I –patients 
under 65 years of age and group II – patients older 
than 65 years of age. Year of birth, size of tumor, 
axillary lymph node status, steroid receptor status 
and HER2 status were determined for all patient.
Patients received adjuvant chemotherapy 
based on antracyclines –AC (Adriamycin 60mg/
m2 and Cyclophosphamide 600 mg/m2) for 6 cy-
cles; AC for 4 cycles followed by paclitaxel for 4 
cycles (175 mg/m2) or non-antracycline based che-
motherapy - CMF (Cyclophosphamide 600mg/m2, 
Methothrexate 40 mg/m2 and 5-Fluorouracil 600 
mg/m2) for 6 cycles in three weeks intervals. After 
adjuvant therapy was completed, treatment was 
continued with trastuzumab every three weeks 
for one year.
Cardiac function was monitored with echo-
cardiography by measuring left ventricle ejection 
fraction (LVEF) in patients before starting trastu-
zumab, 3 months and 8 months after initiation of 
trastuzumab. Patients who developed cardial dys-
function underwent echocardiography after two 
weeks and than every two months until LVEF re-
covered. Cardial dysfunction was defi ned as drop 
in LVEF by ≥ 15% of basal value or ≥ 10% of lower 
normal value (= 50%).
RESULTS
Follow up included 230 patientswith early 
HER2 positive breast cancer in period from Janu-
ary 1st 2007 until December 31st 2009. Median fol-
low up period was 35 months (16-52 months). Pa-
tients were 35 to 77 years old (median 58 years). 
190 (82,6%) were younger than 65 years – group I, 
and 40 (17,4%) were over 65 years – group II.
Biological characteristics of tumor were dif-
ferent regarding patients age: 50% of patients 
younger than 65 years hada tumor smaller than 2 
cm while 75% of patientsover 65 years had a tu-
mor larger than 2 cm. Older patients had statisti-
cally higher incidence of larger tumor, over 2 cm 
(chi2 test, chi=8.32, df=1, p=0.004) (Table 1., Figure 
1). There was no statistically signifi cant diff eren-
ce in axillary lymph node infi ltration between 
groups. 41,6% younger patients vs 42,5% older 
 patients had negative axillary lymph nodes status 
(N0). One to three axillary lymph nodes were pos-
itive (N1) in 23,7% ofyounger vs 20,0% in older 
patients. Metastases in ≥ 4 axillary lymph nodes 
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(N2,N3) were found in 35,7% of younger vs 37,5% 
of older patients.There was no statistically signifi -
cant diff erence in lymph node (N) involvement 
between two groups (chi2 test, chi=0.273, df=2, 
p=0.872) (Table 1., Figure 2).
Hormone sensitivity of tumor was diff erent 
regarding patients age: 56% of younger patients 
had ER/PR negative tumor whereas 62,5% of older 
patients had ER/PR positive tumor. Younger pa-
tients had signifi cantly higher incidence of hor-
mone (ER and PR) negative breast cancer (chi2 
test, chi=15.21, df=1, p<0.001) (Table 1., Figure 3).
Considering the stage of breast cancer: 30% 
of patients in group I had a stage I disease vs 25% 
of patients in group II; 30% of patients in group I 
had a stage II disease vs 45% in group II; 40% of 
patients in group I had a stage III disease vs 30% 
in group II. (Table 2., Figure 4.) There was no sta-
tistically signifi cant diff erence in stages between 
groups (chi2 test, chi=3.43, df=2, p=0.180).
All the patients received adjuvant therapy 
 after surgical treatment; all the patients in young-
er group received anthracycline based regimen 
while 82.5% of older patients received anthracy-
clines. 17.5% of older patients received non-an-
thracycline based chemotherapy (CMF) due to in-
creased cardiovascular risk. Signifi cantly larger 
number of younger patients received anthra-
cycline based chemotherapy (proportion test, p<
0,001). (Figure 5.)
Incidence of cardiac dysfunction was 12,2% 
and there was no statistical diff erence between 
two age groups. Treatment with trastuzumab was 
continued in 69.5% of younger patients after car-
diac therapy and LVEF recovery. None of patients 
older than 65 years continued trastuzumab treat-
ment due to comorbidity, prolonged cardiac re-
covery, benefi t/risk assessmentor due to patients 
personal preferences (Table 3).
Table 1.
HER2 POSITIVE BREAST CANCER CHARACTERISTICS 
REGARDING PATIENTS AGE
Characteristics
Age ≤ 65 years 
(∑N = 190)
Age > 65 years 
(∑N = 40)
N % N %
Tumor size ≤ 2 cm 95 50,0 10 25,0
Tumor size>2 cm 95 50,0 30 75,0
N0 79 41,6 17 42,5
N1 45 23,7 8 20,0
N2 i N3 66 35,7 15 37,5
ER i PR negative 106 56,0 15 37,5
ER i PR positive 84 44,0 25 62,5
Figure 1. Tumor size regarding patients age
Figure 2. Metastases in axillary lymph nodes
Figure 3. Steroid receptor status regarding patients age
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DISCUSSION
In the last few decades there is a trend of age-
ing of population in the world which leads to in-
creased incidence of breast cancer among older 
age groups. There are diff erences in tumor histo-
logical characteristics between younger and older 
patients whose tumors usually show slower 
growth, lower aggressiveness and higher hormo-
ne sensitivity. Older age is associated to signifi -
cant comorbidity which aff ects tolerance to anti-
neoplastic drug and can aff ect treatment choice 
(1,4,8).
In our research17% of patients were older 
than 65 years which leads to conclusion that there 
is lower incidence of HER2 positive tumors in old-
er age groups, e.g. there is a higher incidence of 
less aggressive tumors in older age groups.
Despite tumor size in older group (75% of tu-
mors were larger than 2 cm), there was no statisti-
cally signifi cant diff erence in axillary lymph node 
infi ltration or disease stage which also indicates 
lower tumor aggressiveness. On the other hand, 
women over 69 year are not included in National 
program for early breast cancer detection and they 
usually delay their visit to a doctor, which can ex-
plain signifi cant diff erence in tumor size between 
groups. 62,5% of tumors in older age were hor-
mone sensitive which is consistent with the litera-
ture data (8).
There are diff erences in applied adjuvant 
chemotherapy protocols due to signifi cantly high-
er comorbidity and cardiovascular risk in older 
women. Younger patients received anthracycline 
based chemotherapy more frequently (100%) than 
the older ones (82,5%).
Symptomatic cardiac dysfunction incidence 
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(∑N = 40)
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N % N % N %
≤65 (group I) 190 82,6 23 12,1 16/23 69,5
>65 (group II) 40 17,4 5 12,5 0 0
TOTAL 230 100,0 28 12,2 16 /28 57,0
Table 4.




N % N %
Group I – patients 
with cardiovascular risk (N= 53) 8 15,1 45 84.9
Group II – patients 
with cardiovascular risk (N= 20) 6 30,0 14 70,0
Figure 4. Breast cancer stage regarding patients age
Figure 5. Antracycline based chemotherapy
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ence between groups. Incidence of cardiac dys-
function in patients with cardiovascular risk was 
30% in group of older patients compared to 15% in 
group of younger ones. Similar results, for elderly 
women with cardiovascular risk who received 
trastuzumab, were presented by C. Serrano (32). 
After development of cardiac dysfunction, older 
patients did not continue trastuzumab treatment 
due to prolonged and inadequate recovery of car-
diac function.
CONCLUSION
There are statistically signifi cant diff erences 
in biological characteristics and chemotherapy re-
gimens for HER2 positive early breast cancer in 
elderly women. Incidence of trastuzumab induced 
cardiac dysfunction showed no signifi cant diff er-
ence between younger and older patients except 
in group of older patients with cardiovascular risk 
who had signifi cantly higher incidence of cardiac 
dysfunction.
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